NCT02552953View on ClinicalTrials.gov

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 28, 2015

Primary Completion Date

October 4, 2022

Study Completion Date

August 25, 2023

Conditions
Cancer
Interventions
DRUG

CYC065

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT02552953 - A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers | Biotech Hunter | Biotech Hunter